Symyx Technologies Inc. released the Symyx Direct 6.3 chemistry data cartridge, which now includes new capabilities in the handling of non-specific Markush chemical structures. Symyx Direct enables researchers to register, search and retrieve molecular structures and reactions stored in Oracle(R) relational databases. Used by more than 80% of life sciences organizations worldwide, the cartridge offers proven performance with databases containing over 17 million reactions and over 30 million structures. The new Markush functionality in Symyx Direct supports combinatorial library design and patent claim analysis in drug discovery by greatly expanding the techniques available for managing and exploring large numbers of related chemical substructures. A Markush structure represents a large number of compounds as a single, generic entry by identifying a core structure and listing all possible variants or substitutes using Rgroup notations and substituent lists. Markush structures make it possible to generate and index all possible permutations of a specific chemical entity without creating an unmanageable information repository.

Symyx Technologies Inc. announced it has closed a deal with China Petroleum & Chemical Corporation (Sinopec Corp.) to supply a Zeolite Synthesis Workflow for research in energy and chemical development. This will be the first large-scale implementation of a high-throughput system by Symyx with a Chinese company. The Zeolite Synthesis Workflow utilizes Symyx-pioneered microscale, high-throughput technology for accelerating the pace of breakthrough R&D discoveries. Symyx workflows transform traditional bench science into automated parallel experimentation workflows -- increasing experimental capacity and velocity by 10-100 fold. The Zeolite Synthesis Workflow has been implemented by other companies within the oil and gas industry and has been used internally by Symyx for many years as part of Symyx's research capabilities.

Symyx Technologies Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Third quarter revenue was $35.0 million, compared with $38.9 million for the third quarter of 2008. GAAP net income for the third quarter of 2009, including $2.7 million in discrete income tax benefits, was $1.5 million, or $0.04 per diluted share, compared with a net loss of $745,000, or $0.02 per share, for the comparable quarter last year. Non-GAAP net income for the third quarter of 2009 was $1.8 million, or $0.05 per diluted share, compared with a non-GAAP net loss for the third quarter of 2008 of $1.6 million, or $0.05 per share. Third quarter 2009 Adjusted EBITDA was $4.7 million, or 13% of revenue, up from $2.9 million, or 8% of revenue, for the third quarter last year. Loss from operations was $1.7 million against $4.1 million a year ago. Loss before income tax benefit was $1.1 million against $0.9 million a year ago. Non-GAAP operating income was $2.1 million against operating loss of $5.7 million a year ago. For the nine months period, the company reported net loss of $2.8 million or $0.08 per diluted share on total revenue of $105 million against net loss of $9.1 million or $0.27 per diluted share on total revenue of $116 million reported a year ago. Loss from operations was $7.3 million against $20.1 million a year ago. Loss before income tax benefit was $7.4 million against $14.5 million a year ago. Non-GAAP net income was $1.9 million, or $0.06 per diluted share, compared with a non-GAAP net loss of 2008 of $6.2 million, or $0.18 per share. Non-GAAP operating income was $3 million against operating loss of $15.2 million a year ago. For the fourth quarter of 2009, the company forecasts revenue of $40 million to $45 million and non-GAAP diluted earnings per share of $0.07 to $0.11. The company reported impairment of goodwill of $0.3 million for the third quarter of 2009 as a result of earnout obligations from the purchase of Integrity Biosolution in August 2008.